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Abstract  
Background: Lysergic acid diethylamide (LSD) is a widely used recreational drug. The aim of 
the present study was to develop and validate a liquid chromatography tandem mass 
spectrometry (LC-MS/MS) method for the quantification of LSD, iso-LSD, 2-oxo-3-hydroxy 
LSD (O-H-LSD), and nor-LSD in plasma samples from 24 healthy subjects after controlled 
administration of 100 µg LSD in a clinical trial. In addition metabolites that have been recently 
described in in vitro studies, including lysergic acid monoethylamide (LAE), lysergic acid ethyl-
2-hydroxyethylamide (LEO), 2-oxo-LSD, trioxylated LSD, and 13,14-hydroxy-LSD should be 
identified. Methods: Separation of LSD and its metabolites was achieved on a reversed phase 
chromatography column after turbulent flow online extraction. For the identification and 
quantification a triple-stage quadrupole LC-MS/MS instrument was used. Results: The 
validation data showed slight matrix effects for LSD, iso-LSD, O-H-LSD, or nor-LSD. Mean 
intraday and interday accuracy and precision were 105%/4.81% and 105%/4.35% for LSD, 
98.7%/5.75% and 99.4%/7.21% for iso-LSD, 106%/4.54% and 99.4%/7.21% for O-H-LSD, and 
107%/5.82% and 102%/5.88% for nor-LSD, respectively. The limit of quantification was 0.05 
ng/ml for LSD, iso-LSD, and nor-LSD and 0.1 ng/ml for O-H-LSD. The limit of detection was 
0.01 ng/ml for all compounds.  
Conclusion: The method described herein was accurate, precise, and the calibration range within 
the range of expected plasma concentrations. LSD was quantified in the plasma samples of the 
24 subjects of the clinical trial, whereas iso-LSD, O-H-LSD, nor-LSD, LAE, LEO, 13,14-
hydroxy-LSD, and 2-oxo LSD could only sporadically be detected but were too low for 
quantification. 
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1. Introduction 
 Lysergic acid diethylamide (LSD) is a psychoactive substance that alters states of 
consciousness and perception. Its psychedelic effects made it popular as a recreational drug, 
especially in the 1960s and 1970s, but LSD is still widely used today (1). Additionally, LSD has 
been reintroduced in psychiatric research (2-16) and investigated as an adjunct to psychotherapy 
(17; 18). Therefore, information about its metabolism and pharmacokinetics after controlled 
intake has received increasing interest. Doses that were used in recent clinical studies ranged 
from 75 µg, i.v. (2-11), to 200 µg, p.o. (12-15; 19), resulting in low blood and urine 
concentrations (12; 20). Dolder et al. and Steuer et al. recently showed that LSD and its main 
urinary metabolite 2-oxo-3-hydroxy-LSD (O-H-LSD) were detectable in plasma after controlled 
intake of 200 µg LSD in 16 healthy subjects (12; 20) and clinical toxicological cases of acute 
LSD overdose (21). Studies of in vitro metabolism have further identified lysergic acid mono-
ethyl amide (LAE), lysergic-acid-ethyl-2-hydroxyethylamide (LEO), 2-oxo-LSD, nor-LSD, 
trioxylated-LSD, and 13,14-hydroxy-LSD as glucuronides (22; 23), but no systematic 
information is available regarding their presence in human plasma after controlled intake of 
LSD. However, recent investigations confirmed the presence of 2-oxo-LSD and 13,14-hydroxy-
LSD (glucuronides) in plasma samples after controlled intake of 200 µg LSD (20). The aim of 
the present study was to develop a sensitive turboflow liquid chromatography tandem mass 
spectrometry (LC-MS/MS) method to quantify LSD, iso-LSD, O-H-LSD, and nor-LSD and 
potentially identify LAE, LEO, 2-oxo-LSD, trioxylated-LSD, and 13-14-hydroxy-LSD 
(glucuronides) in human plasma samples. The method was developed using a triple-stage 
quadrupole LC-MS/MS instrument in selected reaction monitoring (SRM) mode after 
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atmospheric pressure ionization (APCI). Our method was established and successfully applied to 
the analysis of plasma samples from healthy volunteers after the intake of 100 µg LSD in a 
controlled clinical study. 
 
2. Materials and methods 
2.1 Chemicals and reagents 
 Acetonitrile, acetone, methanol, 2-propanol, formic acid, and acetic acid with high-
performance liquid chromatography (HPLC)-grade purity were all purchased from Merck 
(Darmstadt, Germany). HPLC-grade ammonium acetate and ammonium carbonate were 
obtained from Merck (Darmstadt, Germany). Distilled water was obtained from an in-house 
installed purifier (ELGA, Bucks, United Kingdom). Drug-free plasma samples (containing 
lithium-heparin as an anticoagulant) serving as negative control, and blank matrices were 
obtained from coworkers. LSD and LSD-d3 as 1 mg/ml reference standards in acetonitrile were 
obtained from Lipomed (Arlesheim, Switzerland). O-H-LSD and iso-LSD as 0.1 mg/ml 
reference standards in acetonitrile were obtained from Cerilliant (Round Rock, TX, USA). Nor-
LSD in powder form was obtained from Toronto Research Chemicals (Toronto, Canada). The 
non-commercially available metabolites LAE, LEO, 2-oxo-LSD, trioxylated-LSD, and 13-14-
hydroxy-LSD (glucuronides) were extracted from pooled 24-h urine samples as described in the 
results section. 
 
2.2 LC-MS/MS analysis 
2.2.1 Equipment 
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 The HPLC system (Transcend TLX1 HPLC, Thermo Scientific, Basel, Switzerland) 
consisted of two Accela 1250 pumps for loading and eluting. The autosampler and sample 
extraction system were controlled by the Aria MX 2.1 software (Thermo Scientific, Basel, 
Switzerland). A cyclone P turboflow column (Thermo Scientific, Basel, Switzerland) was used 
for extraction, and a Zorbax Eclipse XDB-C8 column (Agilent, Santa Clara, CA, USA) was used 
for chromatographic separation. The online extraction system was coupled to a TSQ Endura 
triple stage mass spectrometer (Thermo Scientific, Basel, Switzerland) using APCI in positive 
mode because of its better performance with regard to matrix effects (24; 25). 
 
2.2.2 Liquid chromatography method 
 For LC, three mobile phases were used in gradient mode for extraction and analytical 
chromatography. Mobile phase A consisted of 20 mM ammonium acetate in water and 0.1% 
formic acid. Mobile phase B consisted of 20 mM ammonium acetate in methanol and acetonitrile 
(1:1) that contained 0.1% formic acid. Mobile phase C was an organic mixture of acetonitrile, 
acetone, and 2-propanol (1:1:1). Chromatography was run in isocratic mode with 70% mobile 
phase A and 30% mobile phase B, with a run time of 11 min and 4 additional minutes for 
flushing and equilibration using mobile phase C. 
 
2.2.3 Mass spectrometry conditions 
 The positive ion discharge current was set to 5 µA. The vaporizer temperature was 
optimized to 400°C. Sheath and auxiliary gas provided the best results, with flow rates of 15 and 
5 arbitrary units, respectively. The temperature of the ion transfer tube was set to 300°C. The 
system was tuned and optimized for the detection of LSD. LSD and its metabolites were detected 
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using SRM of the two to three most intense ion transitions. Analytes were identified when 
quantifier and qualifier ions were present within the given retention time. Structures, transitions, 
and respective collision energies are shown in Fig. 1. 
 
2.3 Standard solutions 
 Stock solutions that contained 100 µg/ml LSD, 100 µg/ml LSD-d3, 10 µg/ml iso-LSD, 10 
µg/ml O-H-LSD, or 10 µg/ml nor-LSD in acetonitrile were prepared and stored in light-protected 
brown glass vials at -20°C. All of the solutions were prepared in duplicate to have different sets 
for quality control (QC) and calibration samples. Working solutions of each analyte at 0.1 µg/ml 
in purified water/acetonitrile were used for the preparation of QC and calibration samples and 
matrix and selectivity experiments. Because of the instability of LSD and to minimize possible 
degradation by various freeze-thaw cycles, 1 ml aliquots of stock and working solutions were 
prepared. 
 
2.4 Sample preparation 
 Study samples were sorted according to drug condition (LSD or placebo) and subject 
(S1-24). Calibrators, controls and subject samples were thawed once, and 100 µl aliquots were 
taken to minimize the freeze-thaw cycles. To 100 µl of plasma, 110 µl of an acetonitrile/LSD-d3 
solution (0.01 µg/ml) was added. The samples were then vigorously vortexed and centrifuged for 
10 min at 13,200  g, and the supernatant was then transferred to 96-well plates.  
 
2.5 Experiments 
2.5.1 Calibration 
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 Six calibration standards were prepared by spiking plasma samples with LSD, iso-LSD, 
and nor-LSD to concentrations of  0.05, 0.1, 0.5, 1, 5,  and 10 ng/ml plus blank (matrix only) and 
zero sample (matrix plus internal standard).  Five calibrators were used for O-H-LSD with 
concentrations of 0.05, 0.1, 0.5, 1, 5, and 10 ng/ml plus blank (matrix only) and zero sample 
(matrix plus internal standard). The highest calibration point in plasma was adopted from our 
previously developed method and pharmacokinetic-pharmacodynamic data (12; 21). The 
calibration curves were linearly fitted using a weighting factor of 1/x
2
. 
 
2.5.2 Selectivity 
 Following U.S. Food and Drug Administration validation guidelines (26), we collected 
plasma samples from six different healthy volunteers and tested them for interference to establish 
selectivity. We further analyzed samples from the placebo condition to confirm the absence of 
LSD. 
 
2.5.3 Matrix effects and recovery 
 Matrix effects, recovery, and process efficiency were measured and calculated according 
to Matuszewski et al. (27). In regard of the vulnerability to light and air and because of the online 
extraction that was used in the present method, the extraction step comprised only protein 
precipitation. All of the samples were processed through the turbulent-flow extraction column. 
Five plasma samples were spiked to concentrations between 0.05 and 10 ng/ml for LSD, iso-
LSD, O-H-LSD, and nor-LSD. The samples were measured before and after extraction and in 
neat solution. The peak areas of the spiked samples after extraction were then compared with the 
area of the spiked mobile phase to calculate matrix effects. Recovery values were calculated as 
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the areas of standards that were spiked before extraction divided by the areas of standards that 
were spiked after extraction. The process efficiency was adopted from Matuszewski et al. (27) 
and calculated as the ratio between the area of the standard spiked before extraction and the areas 
of the standard in neat solution.  
2.5.4 Stability 
 The determination of long-term stability was based on Li et al. and Klette et al., in which 
LSD is regarded as stable under storage conditions of -20°C (28; 29). However, LSD is known to 
be very unstable and vulnerable to air, light, and heat. Even ambient temperature (20-25°C) and 
normal light conditions can lead to a decrease in LSD concentrations. Therefore, we assessed 
bench-top stability and autosampler stability with multiple measurements of calibration and QC 
samples within 24 h. For autosampler stability, the samples were kept in light-protected, sealed, 
96-well deep-well plates at 4 °C in the autosampler until injection. During the study, the samples 
were drawn through an intravenous catheter into lithium-heparin tubes and directly centrifuged, 
and the plasma was stored at -20°C at the study site before transferring to the laboratory for 
analysis. Due to the known vulnerability of LSD, calibrators and quality controls were freshly 
weighted every week and single aliquots were stored at -20°C. A new calibration was run every 
day and with every study subject. 
 
2.5.5 Lower limits of detection and quantification 
 Drug-free plasma samples were spiked with different concentrations of LSD, iso-LSD, 
O-H-LSD, and nor-LSD for determination of the limit of quantification (LOQ) and the limit of 
detection (LOD). The LOQ concentrations had to give a response at least 5-times greater than the 
blank. Additionally, precision had to be < 20%, and accuracy had to be 80-120% using at least 
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five determinations per matrix and concentration. The LOD concentration was determined as the 
lowest discriminable peak in the region of a signal-to-noise ratio greater than five. 
 
2.5.6 Carryover 
 For the determination of the carryover, different blank plasma samples were run between 
patient samples, highest calibrations and quality controls. 
 
2.5.7 Reproducibility 
 According to U.S. Food and Drug Administration guidelines (26), the reproducibility of 
quantification was determined by measuring each QC sample five times in 1 day to establish 
intraday precision and accuracy. Each QC sample was also measured for 5 consecutive days to 
determine interday precision and accuracy. All of the values had to meet the criteria of a 
coefficient of variation (CV) < 15%, response < 20% at the LOQ, and accuracy of 80-120%. To 
demonstrate the accuracy and precision of the method, we used three QCs (low, medium, high). 
The QC concentrations were 0.05, 1, and 10 ng/ml for LSD, iso-LSD, and nor-LSD, and 0.1, 1, 
and 10 ng/ml for O-H-LSD, respectively. 
 
3. Results 
 LSD, LSD-d3, iso-LSD, and the metabolites nor-LSD, LAE, LEO, 2-oxo-LSD, 
trioxylated-LSD, and 13-14-hydroxy-LSD (glucuronides) eluted between 4 and 11 min. The 
chromatographic separation of spiked samples and selected metabolites is depicted in Fig. 2A, 
and the chromatogram of a subject’s sample 4 h after LSD administration is presented in Fig. 2B. 
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3.1 Selectivity 
 None of the six plasma samples showed any interference within the measured mass range 
and time frame (Fig 4). Furthermore, none of the measured plasma samples from the placebo 
condition showed any interference.  
 
3.2 Matrix effects and recovery 
 The plasma matrix effects were 125 % for LSD, 119 % for iso-LSD, 103 % for O-H-
LSD, and 118 % for nor-LSD at concentrations of 10 ng/ml, consistent with a slight ion 
enhancement for LSD, iso-LSD and nor-LSD. Recoveries were calculated as 70-90 % for all 
substances at 10 ng/ml. Process efficiencies were 113 % for LSD, 86 % for iso-LSD, 77 % for 
O-H-LSD, and 93 % for nor-LSD.  
 
3.3 Stability 
 The concentrations of the processed samples decreased up to -60% within 24 h at ambient 
temperature (20-23°C). The concentrations of the extracted and sealed plasma samples that were 
stored within the closed autosampler at 4°C were stable up to 24 h. 
 
3.4 Lower limits of detection and quantification 
 The LOQ was 0.05 ng/ml for LSD, iso-LSD, and nor-LSD. For O-H-LSD the respective 
concentration was 0.1 ng/ml. The LODs were 0.01 ng/ml for all compounds. 
 
3.5 Carryover 
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 No carryover was found for LSD, iso-LSD, O-H-LSD, or nor-LSD in the plasma 
samples. Despite these results as a preventive measure a consecutive blank was always run after 
the highest calibrator (10 ng/ml) and QC (10 ng/ml) during method development and the 
measurement of the study samples. 
 
3.6 Linearity 
 Calibration curves in plasma were linear over the respective calibration ranges, with a 
mean correlation coefficient (R
2
) of 0.99. The calibration curves (mean ± SEM) are shown in 
Fig. 3. 
 
3.7 Reproducibility 
 All of the substances fulfilled the accuracy and precision criteria. The mean intraday 
accuracy and precision were 105 % and 4.81 % for LSD, 98.7 % and 5.75 % for iso-LSD, 106 % 
and 4.54 % for O-H-LSD, and 107 % and 5.82 % for nor-LSD, respectively. The mean interday 
accuracy and precision were 105 % and 4.35 % for LSD, 99.4 % and 7.21 % for iso-LSD, 99.4 
% and 7.21 % for O-H-LSD, and 102 % and 5.88 % for nor-LSD, respectively. 
 
3.8 Identification of non-commercially available LSD metabolites 
 LSD metabolites were extracted by liquid-liquid extraction from pooled LSD-positive 24-
h urine samples (8 L) to reach high concentrations. One part of the concentrated metabolites was 
kept for eventual quantification, and the second part was extracted using industrial separation by 
automated thin-layer chromatography and purification. Separation was performed with generous 
support from Camag (Muttenz, Switzerland). Parent masses and selected transitions for LC-MS 
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were adopted from Cai et al. (22) and Canezin et al. (23) and replicated by injecting a mixture of 
the concentrated, extracted metabolites. All of the identified metabolites from concentrated urine 
samples (LAE, LEO, 2-oxo-LSD, trioxylated-LSD, and 13,14-hydroxy LSD) were added to the 
quantification method before validation, for qualitative screening of the study samples.  
 
3.9 Samples 
 LSD (100 μg) and placebo were administered to 24 healthy subjects (12 women, 12 men) 
in a double-blind, randomized, placebo-controlled, cross-over study. The study was conducted in 
accordance with the Declaration of Helsinki and International Conference on Harmonization 
Guidelines in Good Clinical Practice (ICH-GCP) and approved by the Ethics Committee 
Northwest Switzerland and Swiss Federal Office for Public Health, Bern, Switzerland. The study 
was registered at ClinicalTrials.gov (NCT02308969). Plasma samples were collected at baseline 
and 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 h after LSD administration. Maximum LSD plasma 
concentrations of 1.3 ± 0.17 ng/ml (mean ± SEM) were determined. Nor-LSD could only be 
quantified in two subjects (3 and 4 h post-administration), and LAE, LEO, 2-oxy LSD, and 
13,14-hydroxy LSD were detected in some of the samples. 13,14-hydroxy glucuronides were 
undetectable because they were cleaved during ionization. Detailed study descriptions, 
pharmacokinetic data, and pharmacokinetic-pharmacodynamic analyses will be published 
elsewhere. 
 
4. Discussion & Conclusion 
 With mean maximum plasma concentrations of LSD of ~1 ng/ml, the development of 
analytical methods for quantification remains a challenge and brings LC-MS technologies to 
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their limits. For separation of the different analytes, various columns have been used. Especially 
the separation of LSD and iso-LSD was challenging, and only achieved using the Zorbax Eclipse 
XDB-C8 column. However, the method was only developed to chromatographically separate 
LSD, iso-LSD, nor-LSD and O-H-LSD. The non-commercially available metabolites were not 
available in sufficient amounts for extensive experiments. Further, to improve sensitivity, 
different sample preparation procedures (e.g., liquid-liquid extraction using chlorobutane and 
tert-butyl-methylether) have been performed but have not led to significant changes in the LOQ. 
Considering the light sensitivity, the thermal instability of LSD and the manual workload that is 
caused by liquid-liquid extraction or solid-phase extraction, simple and fast protein precipitation 
has been favored instead. APCI was equally to ESI regarding signal intensity but gave slightly 
better results regarding matrix effects and was therefore favored. Overall, quantifying plasma 
samples between 12 and 24 h after LSD administration requires techniques that provide precise 
and sensitive measurements within the low picogram range. This poses a challenge to 
quantifying LSD concentrations and also makes it impossible to quantify or even identify new 
metabolites in plasma samples after controlled intake of 100 µg LSD. In our recent investigations 
(12), we detected quantifiable plasma levels of O-H-LSD after the administration of 200 µg 
LSD. Steuer et al. additionally identified O-H-LSD and 13-14-hydroxy LSD (glucuronides) (20). 
We did not expect to detect quantifiable concentrations of LSD metabolites after the 
administration of 100 µg LSD. The metabolites did not reach the LOD of our or other methods. 
Nevertheless, we sporadically detected the presence of metabolites in some plasma samples and 
could confirm the presence of O-H-LSD, nor-LSD, LEO, LAE, and 13,14-hydroxy LSD in 
plasma. To investigate the metabolism of LSD more comprehensively, further studies that use 
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higher doses of LSD are required and metabolites need to be commercially available to develop 
comprehensive analytical methods for their quantification. 
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Tables  
Table 1 gives the measured plasma concentrations (Cmax) and the corresponding timepoints (Tmax) following oral administration of 
100 µg LSD in 24 healthy subjects.  
Subject 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Cmax (ng/ml) 1.7 1.2 1.2 2.0 2.1 1.5 1.4 1.9 3.3 2.0 0.8 3.2 0.8 0.9 1.4 0.8 1.9 1.3 0.3 1.8 1.9 1.1 1.4 1.2
Tmax (h) 1 1 2 1 3 1 2 2 1 2 3 1 1 2 2 1 1 2 1 2 2 3 2 3
Table 1. Measured LSD plasma concentrations in 24 subjects
 
 
    
Figure Legends 
 
Figure 1. Structure, retention time, ion transitions and collision energies of LSD and selected 
metabolites. 
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Figure 2. (A) Chromatogram of selected metabolites. LSD, iso-LSD, nor-LSD and 2-oxo-3-
hydroxy-LSD are spiked at 1 ng/ml in plasma, the concentration of lysergic-acid 
monoethylamide, lysergic-acid-ethyl-2-hydroxyethylamide, dihydroxy-LSD, and 2-oxo-LSD is 
unknown. 
 
(B) Chromatogram of a healthy volunteer 4 hours after administration of 100 µg LSD. Arrows 
are indicating peaks of LSD (1), iso-LSD (2), nor-LSD (3) and 2-oxo-3-hydroxy-LSD (4), 
lysergic-acid monoethylamide (5), lysergic-acid-ethyl-2-hydroxyethylamide (6), dihydroxy-LSD 
(7), and 2-oxo-LSD (8).  
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Figure 3. Calibration curves of LSD, iso-LSD, nor-LSD, and 2-oxo-3-hydroxy-LSD in human 
plasma. 
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Figure 4. Chromatogram of 6 blank plasma samples from 6 different subjects, and a blank 
sample containing LSD-d3. 
